$-0.22 EPS Expected for ChemoCentryx, Inc. (CCXI)
March 5, 2018 – By Hazel Jackson
Investors sentiment decreased to 1.14 in 2017 Q3. Its down 0.26, from 1.4 in 2017Q2. It fall, as 12 investors sold ChemoCentryx, Inc. shares while 23 reduced holdings. 12 funds opened positions while 28 raised stakes. 23.75 million shares or 2.21% less from 24.29 million shares in 2017Q2 were reported.
Adams Diversified Equity Fund stated it has 0.03% in ChemoCentryx, Inc. (NASDAQ:CCXI). Manufacturers Life Company The accumulated 0% or 21,437 shares. Federated Pa reported 64,610 shares. Artal Group Sa has invested 0.06% in ChemoCentryx, Inc. (NASDAQ:CCXI). Keybank Natl Association Oh owns 40,438 shares or 0% of their US portfolio. Bb&T Secs Lc has 83,500 shares for 0.01% of their portfolio. Piermont holds 0.07% or 27,988 shares in its portfolio. Acadian Asset Mngmt Limited has 497,195 shares for 0.02% of their portfolio. 160,000 are owned by Paw. Macquarie Group Ltd holds 8,631 shares. Bvf Il holds 7.59 million shares or 7.16% of its portfolio. Rhumbline Advisers invested in 0% or 29,953 shares. State Street Corp accumulated 428,004 shares. Meeder Asset Mgmt Incorporated has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Nationwide Fund Advsrs owns 13,828 shares.
Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.22 EPS on March, 13.They anticipate $0.06 EPS change or 37.50 % from last quarter’s $-0.16 EPS. After having $-0.13 EPS previously, ChemoCentryx, Inc.’s analysts see 69.23 % EPS growth. The stock decreased 3.70% or $0.4 during the last trading session, reaching $10.41. About 63,700 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 60.64% since March 5, 2017 and is uptrending. It has outperformed by 43.94% the S&P500.
ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage
Among 3 analysts covering ChemoCentryx (NASDAQ:CCXI), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. ChemoCentryx had 5 analyst reports since September 3, 2015 according to SRatingsIntel. The company was initiated on Tuesday, February 21 by JMP Securities. Cowen & Co maintained the shares of CCXI in report on Tuesday, August 8 with “Hold” rating. The firm has “Sell” rating given on Thursday, September 3 by Zacks. The firm has “Sell” rating by Zacks given on Monday, September 21. The firm earned “Buy” rating on Thursday, August 10 by JMP Securities.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $507.66 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn's diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
Another recent and important ChemoCentryx, Inc. (NASDAQ:CCXI) news was published by Globenewswire.com which published an article titled: “ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on …” on March 01, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.